We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Pfizer Questions Drug ‘Total Content’ in Biosimilar Guidance
Pfizer Questions Drug ‘Total Content’ in Biosimilar Guidance
Pfizer asked the FDA to clarify the term “total content” in its draft guidance for biosimilar development, for demonstrating that a drug and a reference product have the same strength.